Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma

NCT00673361 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Concurrent decrescendo biochemotherapy regimen
DRUG: Low-dose Temozolomide plus Sorafenib

Sponsor

Duke University

Collaborators

[object Object]